- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.08. | Lexeo Therapeutics stock price target lowered to $9 at H.C. Wainwright | 1 | Investing.com | ||
| 15.08. | H.C. Wainwright senkt Kursziel für Lexeo Therapeutics auf 9 US-Dollar | 2 | Investing.com Deutsch | ||
| 14.08. | Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights | 120 | GlobeNewswire (Europe) | Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia... ► Artikel lesen | |
| 14.08. | Lexeo Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.08. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.07. | This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday | 7 | Benzinga.com | ||
| 31.07. | Oppenheimer initiates Lexeo Therapeutics stock with Outperform rating | 7 | Investing.com | ||
| 29.07. | Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO) | 1 | Insider Monkey | ||
| LEXEO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.07. | Lexeo Therapeutics: Aktie schnellt nach Fair-Value-Signal um 96 % in die Höhe | 4 | Investing.com Deutsch | ||
| 07.07. | Lexeo Therapeutics: FDA erteilt "Breakthrough"-Status für Gentherapie - Aktie im Plus | - | Investing.com Deutsch | ||
| 07.07. | Stifel bestätigt Kaufempfehlung für Lexeo Therapeutics nach positivem FDA-Bescheid | 5 | Investing.com Deutsch | ||
| 07.07. | Stifel reiterates Buy rating on Lexeo Therapeutics stock at $21 price target | 2 | Investing.com | ||
| 07.07. | Why Lexeo Is Rising In Pre-market? | 1 | RTTNews | ||
| 07.07. | FDA grants breakthrough therapy designation to Lexeo's FA treatment | 1 | Investing.com | ||
| 07.07. | Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia | 2 | GlobeNewswire (USA) | ||
| 30.06. | Lexeo Therapeutics-Aktionäre wählen Direktoren und bestätigen Wirtschaftsprüfer bei Jahresversammlung | 1 | Investing.com Deutsch | ||
| 30.06. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.06. | Lexeo to help launch spinout around RNA drugs for the heart | 1 | BioPharma Dive | ||
| 24.06. | Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics | 1 | GlobeNewswire (USA) | ||
| 13.06. | Lexeo Therapeutics files to sell 41.63M shares of common stock for holders | 1 | Seeking Alpha |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,461 | +3,16 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results | Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| PROTALIX BIOTHERAPEUTICS | 1,410 | +6,02 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results | Company to host conference call and webcast today at 8:30 a.m. EDT
CARMIEL, Israel, Aug. 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:... ► Artikel lesen | |
| ENZO BIOCHEM | 0,440 | -100,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| REPLIMUNE | 4,700 | +1,73 % | Replimune, Inc.: Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update | WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced... ► Artikel lesen | |
| QUANTERIX | 4,550 | +0,22 % | Quanterix Corporation Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum | BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced... ► Artikel lesen | |
| BELITE BIO | 53,50 | +2,88 % | Belite Bio, Inc: Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA)DRAGON trial completion expected by Q4 2025 (including a three-month... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 58,58 | +0,72 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| IMMUNOVANT | 14,690 | -0,88 % | Immunovant, Inc. - 8-K, Current Report | ||
| ARS PHARMACEUTICALS | 11,610 | -9,72 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
| LENZ THERAPEUTICS | 38,630 | +1,13 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| BIONTECH | 87,40 | +2,10 % | Die Blaupause für KI-Medikamentenentwicklung: So nutzen Evotec, NetraMark Holdings und BioNTech die neuen Möglichkeiten | Die Pharmabranche befindet sich mitten in einer Revolution. Künstliche Intelligenz verkürzt die Wirkstoffentwicklung von Jahren auf Monate und steigert die Trefferquote dramatisch. Datengetriebene Prognosen... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,710 | -2,91 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
| AVIDITY BIOSCIENCES | 46,540 | -4,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 19,120 | -0,52 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2025 Financial Results | Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient... ► Artikel lesen |
Das Unternehmen LEXEO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,84 % bei einem Aktienkurs von 4,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXEO THERAPEUTICS INC finden Sie auf Wallstreet Online.